Compare IH & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IH | CSBR |
|---|---|---|
| Founded | 1996 | 1985 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.0M | 100.1M |
| IPO Year | 2020 | 1986 |
| Metric | IH | CSBR |
|---|---|---|
| Price | $1.84 | $6.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 14.2K | 7.2K |
| Earning Date | 12-29-2025 | 03-10-2026 |
| Dividend Yield | ★ 4.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | 0.17 |
| Revenue | ★ $119,261,855.00 | $58,424,000.00 |
| Revenue This Year | $39.02 | $4.84 |
| Revenue Next Year | N/A | $11.51 |
| P/E Ratio | ★ $6.57 | $40.63 |
| Revenue Growth | N/A | ★ 9.06 |
| 52 Week Low | $1.60 | $5.59 |
| 52 Week High | $3.60 | $11.99 |
| Indicator | IH | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 29.09 | 51.02 |
| Support Level | $1.80 | $6.77 |
| Resistance Level | $1.95 | $7.45 |
| Average True Range (ATR) | 0.08 | 0.25 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 10.02 | 40.90 |
iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.